scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agency10.33647/2713-0428-17-3E-144-146scbmt-1330Research ArticleДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ В БИОМЕДИЦИНЕNON-CLINICAL RESEARCH IN BIOMEDICINEВлияние эмпаглифлозина на течение неалкогольной жировой болезни печени в экспериментеEffects of empagliflosin on the course of non-alcoholic fatty liver disease in experimentБунятА. В.BunyatA. V.

197022, Санкт-Петербург, ул. Профессора Попова, 14, лит. А

197376, Saint Petersburg, Professora Popova Str., 14, let. A

anna.tkacheva@pharminnotech.comСухановД. С.SukhanovD. S.

д.м.н., проф., 

197022, Санкт-Петербург, ул. Профессора Попова, 14, лит. А

Dr. Sci. (Med.), Prof., 

197376, Saint Petersburg, Professora Popova Str., 14, let. A

dmitriysukhanovl@mail.ruФГБОУ ВO «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава РоссииРоссияSaint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Сare of RussiaRussian Federation202126102021173E144146Copyright © Бунят А.В., Суханов Д.С., 20212021Бунят А.В., Суханов Д.С.Bunyat A.V., Sukhanov D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/1330

Оценено влияние препарата группы ингибиторов SGLT-2 эмпаглифлозина на биохимическую и гистологическую картину неалкогольной жировой болезни печени у мышей. 

Effects of the SGLT-2 drug of the group of empagliflozin inhibitors on the biochemical and histological picture of non-alcoholic fatty liver disease in mice was evaluated. 

неалкогольная жировая болезнь печениэмпаглифлозинмышистеатозвысокожировая диетатетрахлорметанэпидидимальный жирвисцеральный жирnon-alcoholic fatty liver diseaseempagliflozinmicesteatosishigh-fat dietcarbon tetrachlorideepididymal fatvisceral fatReferencesCastro R.E., Diehl A.M. Towards a definite mouse model of NAFLD. Journal of Hepatology. 2018;69:272–274.Castro R.E., Diehl A.M. Towards a definite mouse model of NAFLD. Journal of Hepatology. 2018;69:272–274.Haya A., Ilhame D., Maha V., et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J. of Transl. Med. 2019;19:348.Haya A., Ilhame D., Maha V., et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J. of Transl. Med. 2019;19:348.Monami M., Nardini C., Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 2014;16:457– 466.Monami M., Nardini C., Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 2014;16:457– 466.Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., Takasu T., Imamura M., Li Q., Tomiyama H., Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013;715:246–255.Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., Takasu T., Imamura M., Li Q., Tomiyama H., Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013;715:246–255.

The authors declare that there are no conflicts of interest present.